Loading clinical trials...
Loading clinical trials...
A Four-Part, Open-Label Study to Evaluate the Effects of Repeat Dose GSK2118436 on the Single Dose Pharmacokinetics of Warfarin, the Effects of Repeat Dose Oral Ketoconazole and Oral Gemfibrozil on the Repeat Dose Pharmacokinetics of GSK2118436, and the Repeat Dose Pharmacokinetics of GSK2118436 in Subjects With BRAF Mutant Solid Tumors
Conditions
Interventions
Warfarin
Ketoconazole
+3 more
Locations
11
United States
GSK Investigational Site
Scottsdale, Arizona, United States
GSK Investigational Site
Sarasota, Florida, United States
GSK Investigational Site
Detroit, Michigan, United States
GSK Investigational Site
Columbus, Ohio, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Greenville, South Carolina, United States
Start Date
September 3, 2012
Primary Completion Date
November 14, 2012
Completion Date
November 14, 2012
Last Updated
November 13, 2017
NCT05198830
NCT05039801
NCT05053971
NCT03191149
NCT04929028
NCT05673200
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions